Review
Gastroenterology & Hepatology
Leon D. Averbukh, Alla Turshudzhyan, David C. Wu, George Y. Wu
Summary: Since their introduction in 1987, statins have become widely prescribed medications, but they have been associated with side effects such as mild liver dysfunction. Statin-induced liver injury can present as hepatocellular or cholestatic patterns, with severe liver injury being rare.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Ana Petrovic, Sonja Vukadin, Renata Sikora, Kristina Bojanic, Robert Smolic, Davor Plavec, George Y. Wu, Martina Smolic
Summary: Anabolic androgenic steroids have therapeutic benefits but are commonly misused and have detrimental effects on various organs, particularly the liver. This article reviews the latest knowledge on the adverse effects of anabolic androgenic steroids on the liver and their mechanisms.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Chemistry, Multidisciplinary
Qi-Wen Chen, Qian-Ru Li, Meng-Wei Cao, Jian-Hua Yan, Xian-Zheng Zhang
Summary: Cholestatic drug-induced liver injury (DILI), a severe clinical syndrome, can be effectively prevented by living materials consisting of dual probiotics that modulate the gut-liver axis. The constructed materials release probiotic Lactobacillus rhamnosus GG in the intestines, which inhibits hepatic bile acid synthesis and promotes bile acid excretion. Additionally, the materials absorb excessive bile acids and decrease their total amount in the enterohepatic circulation.
Review
Pharmacology & Pharmacy
Xinghui Li, Jiaqi Ni, Li Chen
Summary: This review focuses on the diagnosis, screening, and management of Acetaminophen (APAP)-induced liver injury (AILI), which is a significant cause of drug-induced liver injury and acute liver failure. It summarizes recent research progress, highlights current issues, and provides recommendations for future research.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Critical Care Medicine
Pedro David Wendel-Garcia, Rolf Erlebach, Daniel Andrea Hofmaenner, Giovanni Camen, Reto Andreas Schuepbach, Christoph Juengst, Beat Muellhaupt, Jan Bartussek, Philipp Karl Buehler, Rea Andermatt, Sascha David
Summary: This study found a dose-response relationship between long-term infusion of ketamine and elevated bilirubin levels in COVID-19 patients. It also revealed an increased risk of cholestatic liver injury associated with ketamine. Therefore, the long-term use of high-dose ketamine should be avoided in mechanically ventilated COVID-19 patients.
Article
Chemistry, Multidisciplinary
Kai-li Fu, Pan Chen, Yan-ying Zhou, Yi-ming Jiang, Yue Gao, Hui-zhen Zhang, Li-huan Guan, Cong-hui Wang, Jun-ling Liu, Min Huang, Hui-chang Bi
Summary: Hepatic deficiency of Vps33b exacerbates cholestatic liver injury, leading to abnormal serum markers and liver function, as well as altered metabolism of bile acids. Metabolomics analysis reveals that Vps33b deficiency changes the profile of bile acids, accompanied by alterations in gene expression of bile acid metabolizing enzymes and transporters.
ACTA PHARMACOLOGICA SINICA
(2022)
Review
Pharmacology & Pharmacy
Xichuan Li, Wanting Wang, Suying Yan, Weipeng Zhao, Hui Xiong, Cuiping Bao, Jinqian Chen, Yuan Yue, Yanjun Su, Chunze Zhang
Summary: The COVID-19 outbreak has caused significant global health and economic losses. This review examines drug-induced liver injury (DILI) in COVID-19 patients treated with antiviral drugs, such as favipiravir, remdesivir, lopinavir/ritonavir, and hydroxychloroquine. We discuss the incidence, mechanisms, and surveillance strategies of DILI, as well as medication recommendations for preserving liver function in COVID-19 patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sabine Weber, Alexander L. Gerbes
Summary: Drug-induced liver injury (DILI) is a rare but potentially severe adverse drug event, which poses a major challenge for diagnosis in clinical practice and pharmacovigilance. Efforts have been made to establish diagnostic testing methods and biomarkers for safe diagnosis and differentiation from other liver diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Gastroenterology & Hepatology
Steven Trinh, Nicholas Batt, Rohit Sawhney, Amanda Nicoll
Summary: Drug-induced liver injury (DILI) is a rare cause of acute liver injury. Bjornsson et al. establish a European DILI registry to assess the clinical features and outcomes of DILI in several European countries. The authors highlight the need for reporting potential outcomes from pharmacotherapy to determine the role of medical therapy for DILI, as this information is currently lacking.
LIVER INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Monika Pazgan-Simon, Sylwia Serafinska, Michal Kukla, Marta Kucharska, Jolanta Zuwala-Jagiello, Iwona Buczynska, Kamila Zielinska, Krzysztof Simon
Summary: Liver injury caused by COVID-19 is mild, with 20% of cases showing improvement by the end of hospitalization. While liver injury does not seem to increase the risk of mortality, caution and monitoring are advised for patients whose liver function tests have not returned to normal levels.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Meng Li, Qiong Luo, Yanyan Tao, Xin Sun, Chenghai Liu
Summary: This article reviews the accumulated literature on drug-induced liver injury (DILI) with evidence-based medicine researches and discusses the limitations of clinical studies and the prospective development for DILI therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Katerina Roma, Salman Mohammed, Blake Sieck, Katrina Naik, Shahid Wahid
Summary: Alternative medicine supplements, such as kratoms, have become a significant cause of liver injury in the US. Reports of adverse events linked to kratom use are increasing, including liver injury, organ dysfunction, and even death. The need for increased regulation and public awareness of the risks associated with kratom is emphasized.
JOURNAL OF HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Haseeb Mohideen, Hafsa Hussain, Dushyant Singh Dahiya, Hisham Wehbe
Summary: Selective androgen receptor modulators (SARMs) are nonsteroidal drugs used for various diseases, but are also used illicitly by bodybuilders and athletes as performance enhancing drugs. Cases of drug-induced liver injury (DILI) from SARMs have started to emerge, sharing similarities with DILI from anabolic androgenic steroids (AASs). These liver injuries present with cholestatic syndrome and can improve with cessation of SARM use, but further research is needed for diagnosis, management, and complications of SARM-related DILI.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chunjiang Wang, Hongyi Deng, Yunfei Xu, Ying Liu
Summary: Metformin-induced hepatotoxicity is a rare adverse reaction. Clinical symptoms include gastrointestinal reactions, jaundice, and fatigue. Abnormalities in blood tests and liver imaging are common. Liver function can recover to normal levels after discontinuation of metformin.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Paul Wasuwanich, Hassan Choudry, Joshua M. So, Sarah Lowry, Wikrom Karnsakul
Summary: This study collected 59 cases of Vanishing bile duct syndrome (VBDS) and drug-induced liver injury (DILI) case reports, finding that antibiotics were the most common offending agents and higher bilirubin levels were associated with poor outcomes.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Zhou Yuming, Tang Ruqi, Merrill Eric Gershwin, Ma Xiong
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Inbal Houri, Gideon M. Hirschfield
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Yasameen Muzahim, Ali Wakil, Mehak Bassi, Nikolaos Pyrsopoulos
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Brian H. Horwich, Douglas T. Dieterich
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Aparna Goel, Paul Kwo
Summary: The goal of autoimmune hepatitis treatment is achieving clinical and biochemical remission. Standard care involves induction treatment with corticosteroids and gradual tapering of steroids. Alternatives to standard therapy can be considered for patients with intolerance or inadequate response. Treatment withdrawal is achievable in less than 20% of patients after 2 years of sustained remission, and liver transplantation should be considered for patients with progressive disease or complications.
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Mariana Zapata, Hendrick Pagan-Torres, Marlyn J. Mayo
CLINICS IN LIVER DISEASE
(2024)
Article
Gastroenterology & Hepatology
Aalam Sohal, Sanya Kayani, Kris Kowdley
Summary: Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease characterized by inflammation and fibrosis of bile ducts. It is commonly associated with inflammatory bowel disease, especially ulcerative colitis. The natural history of the disease varies among patients, but most will develop cirrhosis.
CLINICS IN LIVER DISEASE
(2024)